About In-Silico Sciences, Inc.
Company Name: In-Silico Sciences Inc.
President: Kinji Fuchikami
Director: Katsuichiro Komatsu
Director: Tsuyoshi Matsuki
Director: Marina Unno
Auditor: Hiroshi Hishinuma
Foundation: November 26, 2003
Reorganization to a stock company: June 13, 2003
Capital: 20,112,000 yen
Our main aim is to contribute to the society by returning
academic knowledge, especially by providing softwares that
predict tertiary structures of proteins, drug design
technology, and data bases of protein 3-D structures, which
have been developed over 20 years by a group in School of
Pharmaceutical Sciences, Kitasato University led by Professor
Hideaki Umeyama, to domestic and international academic
institutions and private companies. We also intend to create a
new academic paradigm and a new industry, as a leader of the
epoch of the post-genome sequencing.
- To give licenses of the softwares (PDFAMS) for predicting
protein structures, and drug design.
- To give licenses of the database of protein structures of more
than one million species, obtained with PDFAMS.
- To bear intellectual properties in the fields of designing
drugs, agricultural chemicals, and industrial enzymes, where the
structure of proteins is the most important, by using
PDFAMS Extra (this software has excellent records in CAFASP, a biennial international
competition of prediction of protein structures), mainly by
collaborating with companies and academic institutions.
Products and Services: Custom modeling services of protein structures and ligands
Sales of protein structure
Softwares for predicting tertiary structures of proteins
Data base system of tertiary structures of proteins
The company has already obtained many patents, and plans to apply
and obtain more patents.
Copyright (C) 2003 In-Silico Sciences Inc. All Rights Reserved